The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Open accessAbstract
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 ( IDH1 ) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown. We have shown that tumor-derived IDH1 mutations impair the enzyme's affinity for its substrate and dominantly inhibit wild-type IDH1 activity through the formation of catalytically inactive heterodimers. Forced expression of mutant IDH1 in cultured cells reduces formation of the enzyme product, α-ketoglutarate (α-KG), and increases the levels of hypoxia-inducible factor subunit HIF-1α, a transcription factor that facilitates tumor growth when oxygen is low and whose stability is regulated by α-KG. The rise in HIF-1α levels was reversible by an α-KG derivative. HIF-1α levels were higher in human gliomas harboring an IDH1 mutation than in tumors without a mutation. Thus, IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HIF is stabilized in IDH-associated gliomas; this has been proposed to be a consequence of intracellular depletion of 2OG following IDH loss of function (Zhao et al, 2009).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Zhao et al, 2009
In the citing paper
“The IDH mutations occur at substrate-binding arginine residues (Arg 132 in IDH1; Arg 140 and Arg 172 in IDH2) and inactivate IDH for conversion of isocitrate to 2-oxoglutarate (2OG; Zhao et al, 2009).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Zhao et al, 2009
In the citing paper
“Overexpression of IDH1 Arg 132 mutants results in elevated HIFa levels (Zhao et al, 2009).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Zhao et al, 2009
In the citing paper
“The stability of HIF‐1α is regulated by α‐KG, and increasing α‐KG reduces the expression of HIF‐1α.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [168]
In the citing paper
“Inhibiting the mitochondrial enzyme SDH during ischaemia by preloading tissues with the SDH inhibitor DMM prevented succinate accumulation during ischaemia and protected against tissue damage upon reperfusion150.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [150]
In the citing paper
“succinate accumulated during ischaemia and is then oxidised upon reperfusion to drive the mitochondrial superoxide formation that contributes to ischaemia-reperfusion (IR) injury150,151.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Xu, X., Zhao, J., Xu, Z., Peng, B., Huang, Q., Arnold, E., & Ding, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404298200 · Cited by 407
Self-citationBleeker, F. E., Lamba, S., Leenstra, S., Troost, D., Hulsebos, T. J. M., Vandertop, W. P., Frattini, M., Molinari, F., Knowles, M. A., Cerrato, A., et al. (2009) · Human Mutation · doi:10.1002/humu.20937 · Cited by 365
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
MacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., Watson, D. G., & Gottlieb, E. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01927-06 · Cited by 359
Cellular concentrations of enzymes and their substrates
Albe, K. R., Butler, M. H., & Wright, B. E. (1990) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(05)80266-8 · Cited by 318
Multiple NADPH-producing pathways control glutathione (GSH) content in retina
Winkler, B. S., Desantis, N. M., & Solomon, F. (1986) · Experimental Eye Research · doi:10.1016/s0014-4835(86)80013-6 · Cited by 107
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 999
Anaplastic Glioma: How to Prognosticate Outcome and Choose a Treatment Strategy
DeAngelis, L. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5985 · Cited by 54
Gaster, M., Nehlin, J. O., & Minet, A. D. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.656653 · Cited by 55
Liu, T., Cheng, G., Kang, X., Xi, Y., Zhu, Y., Wang, K., Sun, C., Ye, J., Li, P., & Yin, H. J. (2018) · Neuroradiology · doi:10.1007/s00234-018-2021-5 · Cited by 53
Weller, M., Wick, W., & von Deimling, A. (2011) · Glia · doi:10.1002/glia.21130 · Cited by 50
Protein lysine acetylation guards metabolic homeostasis to fight against cancer
Xu, W., Li, Y., LIU, C., & Zhao, S. (2013) · Oncogene · doi:10.1038/onc.2013.163 · Cited by 53
Self-citationHypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma
Pistollato, F., Abbadi, S., Rampazzo, E., Viola, G., Puppa, A. D., Cavallini, L., Frasson, C., Persano, L., Panchision, D. M., & Basso, G. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.003 · Cited by 51
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 50
Yang, X., Du, T., Wang, X., Zhang, Y., Hu, W., Du, X., Miao, L., & Han, C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.027 · Cited by 51
Glioma-derived mutations in IDH: From mechanism to potential therapy
Fu, Y., Huang, R., Du, J., Yang, R., An, N., & Liang, A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.05.115 · Cited by 52
IDH mutation-specific radiomic signature in lower-grade gliomas
Liu, X., Li, Y., Li, S., Fan, X., Sun, Z., Yang, Z., Wang, K., Zhang, Z., Jiang, T., Liu, Y., et al. (2019) · Aging · doi:10.18632/aging.101769 · Cited by 51
Physical Exercise and Epigenetic Modulation: Elucidating Intricate Mechanisms
Sanchis-Gomar, H. P.-G., & a-Gimenez, J. G. ́. (2014) · Cited by 51
Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights
Ng, K., Kim, R., Kesari, S., Carter, B. S., & Chen, C. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0714-2 · Cited by 50
Barliya, T., Mandel, M., Livnat, T., Weinberger, D., & Lavie, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022849 · Cited by 50
Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy
Hargrave, D. R. (2009) · British Journal of Neurosurgery · doi:10.1080/02688690903158809 · Cited by 50
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment
Speetjens, F. M., de Jong, Y., Gelderblom, H. A. J., & Bovée, J. V. M. G. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000300 · Cited by 50
Nutrient Exploitation within the Tumor–Stroma Metabolic Crosstalk
Morandi, A., Giannoni, E., & Chiarugi, P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.001 · Cited by 50
Immunometabolism: A new target for improving cancer immunotherapy
Guo, C., Chen, S., Liu, W., Ma, Y., Li, J., Fisher, P. B., Fang, X., & Wang, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.004 · Cited by 56
Yao, J., Chakhoyan, A., Nathanson, D. A., Yong, W. H., Salamon, N., Raymond, C., Mareninov, S., Lai, A., Nghiemphu, P. L., Prins, R. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz078 · Cited by 51
Wenger, R. H., & Kurtz, A. (2011) · Comprehensive physiology · doi:10.1002/cphy.c100075 · Cited by 55
Deregulated signalling networks in human brain tumours
Grzmil, M., & Hemmings, B. A. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.10.018 · Cited by 49
Vissers, L. E. L. M., Fano, V., Martinelli, D., Campos‐Xavier, B., Barbuti, D., Cho, T., Dursun, A., Kim, O. H., Lee, S. H., Timpani, G., et al. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34325 · Cited by 49
Walker, O. S., Elsässer, S. J., Mahesh, M., Bachman, M., Balasubramanian, S., & Chin, J. W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b07627 · Cited by 49
Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma
Huang, H., Li, S., Tang, Q., & Zhu, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680955 · Cited by 49
Epigenetic alterations in acute myeloid leukemias
Mehdipour, P., Santoro, F., & Minucci, S. (2014) · FEBS Journal · doi:10.1111/febs.13142 · Cited by 55
Molecular population genetics and selection in the glycolytic pathway
Eanes, W. F. (2010) · Journal of Experimental Biology · doi:10.1242/jeb.046458 · Cited by 48
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications
Gupta, R., Webb-Myers, R., Flanagan, S., & Buckland, M. E. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200227 · Cited by 49
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A., Goparaju, R., Schwarzer, A., Görlich, K., Schottmann, R., Struys, E. A., Jansen, E. E. W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.71 · Cited by 50
Sensitivity of hematopoietic stem cells to mitochondrial dysfunction by SdhD gene deletion
Bejarano-García, J. A., Millán‐Uclés, Á., Rosado, I. V., Sánchez‐Abarca, L. I., Caballero‐Velázquez, T., Durán-Galván, M. J., Pérez‐Simón, J. A., & Piruat, J. I. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.411 · Cited by 54
Krichevsky, A. M., & Uhlmann, E. J. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00702-3 · Cited by 48
Expanding the spectrum of IDH1 mutations in gliomas
Gupta, R., Flanagan, S., Li, C. C. Y., Lee, M. C., Shivalingham, B., Maleki, S., Wheeler, H., & Buckland, M. E. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.210 · Cited by 48
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Fruchtman, H., Avigan, Z. M., Waksal, J. A., Brennan, N., & Mascarenhas, J. O. (2024) · Leukemia · doi:10.1038/s41375-024-02246-2 · Cited by 59
Diagnostic and prognostic markers in gliomas
Ducray, F., Hallani, S. E., & Idbaïh, A. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833065a7 · Cited by 47
Fu, Y., Zheng, S., Zheng, Y., Huang, R., An, N., Liang, A., & Hu, C. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.01.017 · Cited by 49
Li, S. C., Tachiki, L. M. L., Kabeer, M. H., Dethlefs, B. A., Anthony, M. J., & Loudon, W. G. (2014) · Cancer Cell International · doi:10.1186/s12935-014-0115-7 · Cited by 47
From Systems to Structure: Bridging Networks and Mechanism
Fraser, J. S., Gross, J. D., & Krogan, N. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.003 · Cited by 47
Glial Progenitors as Targets for Transformation in Glioma
Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 47
Rakheja, D., Medeiros, L. J., Bevan, S., & Chen, W. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00169 · Cited by 47
Hou, P., Kuo, C., Cheng, C.-T., Liou, J., Ann, D. K., & Chen, Q. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113865 · Cited by 46
IDH1/IDH2but NotTP53Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
Stancheva, G. S., Goranova, T., Laleva, M., Kamenova, M. A., Mitkova, A. V., Velinov, N., Poptodorov, G., Mitev, V., Kaneva, R. P., & Gabrovsky, N. (2014) · BioMed Research International · doi:10.1155/2014/654727 · Cited by 46
HIF1α Expression under Normoxia in Prostate Cancer— Which Pathways to Target?
Ranasinghe, W. K. B., Baldwin, G. S., Bolton, D. M., Shulkes, A., Ischia, J. J., & Patel, O. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.10.085 · Cited by 47
Critical role of TRPC6 in maintaining the stability of HIF-1α in glioma cells under hypoxia
Li, S., Wang, J., Yi, W., Liu, Y., Ding, X., Dong, B., Xu, Y., & Wang, Y. (2015) · Journal of Cell Science · doi:10.1242/jcs.173161 · Cited by 46
Madala, H. R., Punganuru, S. R., Arutla, V., Misra, S., Thomas, T., & Srivenugopal, K. S. (2018) · Cancers · doi:10.3390/cancers10020049 · Cited by 46
Viswanath, P., Radoul, M., Izquierdo-García, J. L., Luchman, H. A., Cairncross, J. G., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0178-3 · Cited by 48
Rescue of TCA Cycle Dysfunction for Cancer Therapy
Marquez, J. C., Flores, J., Kim, A. H., Nyamaa, B., Nguyen, A. T. T., Park, N., & Han, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122161 · Cited by 47
Post-translational modifications on mitochondrial metabolic enzymes in cancer
Peng, Y., Liu, H., Liu, J., & Long, J. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.12.264 · Cited by 49
Self-citationEpigenetic enzyme mutations as mediators of anti-cancer drug resistance
Chen, S., Zhao, Y., Liu, S., Zhang, J., Assaraf, Y. G., Cui, W., & Wang, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100821 · Cited by 47
Metabolite regulation of epigenetics in cancer
Wang, P., Chen, L., Xiong, Y., & Ye, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114815 · Cited by 50
Self-citationMutant IDH1 inhibits PI3K/Akt signaling in human glioma
Birner, P., Pusch, S., Christov, C., Mihaylova, S., Toumangelova‐Uzeir, K., Natchev, S., SCHOPPMANN, S. F., Tchorbanov, A. I., Streubel, B., Tuettenberg, J., et al. (2014) · Cancer · doi:10.1002/cncr.28732 · Cited by 46
Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation
Kaneko, M. K., Tian, W., Takano, S., Suzuki, H., Sawa, Y., Hozumi, Y., Goto, K., Yamazaki, K., Kitanaka, C., & Kato, Y. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.102 · Cited by 45
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma
Fathi, A. T., Nahed, B. V., Wander, S. A., Iafrate, A. J., Borger, D. R., Hu, R., Thabet, A., Cahill, D. P., Perry, A. M., Joseph, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0342 · Cited by 46
Bhavya, B., Reghuvaran, A. C., Madhusoodanan, U. K., Rajalakshmi, P., Krishnakumar, K., Easwer, H. V., Deepti, A. N., & Gopala, S. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00730-3 · Cited by 46
Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
Gilbert, A., Tudor, M., Montanari, J., Commenchail, K., Savu, D., Lesueur, P., & Chevalier, F. (2023) · Cancers · doi:10.3390/cancers15071962 · Cited by 51
Malzkorn, B., Wolter, M., Riemenschneider, M. J., & Reifenberger, G. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00536.x · Cited by 44
Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism
DeLaBarre, B., Hurov, J., Cianchetta, G., Murray, S., & Dang, L. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.007 · Cited by 45
Imaging Genomics of Glioblastoma
Elbanan, M., Amer, A. M., Zinn, P. O., & Colen, R. R. (2014) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2014.09.010 · Cited by 45
Schmierer, B., Novák, B., & Schofield, C. J. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-139 · Cited by 44
Tarhonskaya, H., Nowak, R. P., Johansson, C., Szykowska, A., Tumber, A., Hancock, R. L., Lang, P. A., Flashman, E., Oppermann, U. C. T., Schofield, C. J., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.08.007 · Cited by 45
Molecular markers of paragangliomas/pheochromocytomas
Zhikrivetskaya, S. O., Snezhkina, A. V., Zaretsky, A. R., Alekseev, B. Y., Pokrovsky, A. V., Golovyuk, A. L., Melnikova, N. V., Stepanov, O. A., Kalinin, D. V., Moskalev, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15201 · Cited by 45
Singh, K., Krug, L., Basu, A., Meyer, P., Treiber, N., Beken, S. V., Wlaschek, M., Kochanek, S., Bloch, W., Geiger, H., et al. (2017) · Stem Cells · doi:10.1002/stem.2629 · Cited by 44
Zhou, Z., Ibekwe, E., & Chornenkyy, Y. (2018) · Antioxidants · doi:10.3390/antiox7010016 · Cited by 44
Molecular biology of gliomas: present and future challenges
Altieri, R., Agnoletti, A., Quattrucci, F., Garbossa, D., Specchia, F. M. C., Bozzaro, M., Fornaro, R., Mencarani, C., Lanotte, M., Spaziante, R., et al. (2014) · Europe PMC (PubMed Central) · doi:10.14273/unisa-442 · Cited by 42
Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy
Sen, E. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.003 · Cited by 42
Jha, P., Suri, V. S., Sharma, V., Singh, G., Sharma, M. C., Pathak, P., Chosdol, K., Jha, P., Suri, A., Mahapatra, A. K., et al. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.04.017 · Cited by 42
Lazović, J., Soto, H., Piccioni, D. E., Ru, J. R. L., Li, S., Mirsadraei, L., Yong, W. H., Prins, R. M., Liau, L. M., Ellingson, B. M., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos258 · Cited by 42
Liao, C., Li, M., Li, X., Li, N., Zhao, X., Wang, X., Song, Y., Quan, J., Cheng, C., Liu, J., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.158540 · Cited by 40
The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
Song, P., Zhang, J., Tan, X., Huang, Y., Xu, J., Silk, N., Zhang, D., Liu, Q., & Jiang, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.586857 · Cited by 42
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
Choate, K. A., Pratt, E. P. S., Jennings, M. J., Winn, R. J., & Mann, P. B. (2024) · Biology · doi:10.3390/biology13110885 · Cited by 49
IDH1 mutation of gliomas with long-term survival analysis
Myung, J. K., Cho, H. J., Park, C., Kim, S., Phi, J. H., & Park, S. (2012) · Oncology Reports · doi:10.3892/or.2012.1994 · Cited by 41
Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells
Watanabe, A., Ogiwara, H., Ehata, S., Mukasa, A., Ishikawa, S., Maeda, D., Ueki, K., Ino, Y., Todo, T., Yamada, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906930108 · Cited by 41
Immunotherapy for malignant glioma
Suryadevara, C. M., Sanchez-Perez, L. A., Sampson, J. H., Verla, T. G., Reap, E. A., Choi, B., & Fecci, P. E. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.151341 · Cited by 42
Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41
Lactate stimulates CA IX expression in normoxic cancer cells
Pánisová, E., Kery, M., Sedlakova, O., Brisson, L., Debreova, M., Sboarina, M., Sonveaux, P., Pastoreková, S., & Švastová, E. (2017) · Oncotarget · doi:10.18632/oncotarget.20836 · Cited by 41
Juratli, T. A., Peitzsch, M., Geiger, K. D., Schackert, G., Eisenhofer, G., & Krex, D. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not006 · Cited by 40
Liu, W., Chan, S., Chang, H., Li, G., Tu, Y.-T., Tseng, H., Fu, T., Chang, H.-Y., Liou, H., Ger, L., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0953-7 · Cited by 40
Gulaia, V. S., Kumeiko, V. V., Shved, N. A., Cicinskas, E., Александрович, Р. С., Ruzov, A. S., & Kagansky, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00388 · Cited by 39
Metabolic Rewiring in Response to Biguanides Is Mediated by mROS/HIF-1a in Malignant Lymphocytes
Khan, H., Anshu, A., Prasad, A. K., Roy, S., Jeffery, J. J., Kittipongdaja, W., Yang, D. T., & Schieke, S. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.007 · Cited by 42
Sandulache, V. C., & Myers, J. N. (2011) · Head & Neck · doi:10.1002/hed.21664 · Cited by 38
Zhu, H., Zhang, Y., Chen, J., Qiu, J., Huang, K., Wu, M., & Xia, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169038 · Cited by 39
González, R., Molina-Ruiz, F. J., Bárcena, J. A., Padilla, C. A., & Muntané, J. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7072 · Cited by 39
Targeting glioma-initiating cells via the tyrosine metabolic pathway
Yamashita, D., Bernstock, J. D., Elsayed, G., Sadahiro, H., Mohyeldin, A., Chagoya, G., Ilyas, A., Mooney, J. H., Estévez-Ordoñez, D., Yamaguchi, S., et al. (2020) · Journal of neurosurgery · doi:10.3171/2019.11.jns192028 · Cited by 38
Cintio, F. D., Bo, M. D., Baboçi, L., Mattia, E. D., Polano, M., & Toffoli, G. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.603647 · Cited by 41
Gu, Y., Yang, R., Yang, Y., Zhao, Y., Wakeham, A. C., Li, W. Y., Tseng, A., Leca, J., Berger, T., Saunders, M. E., et al. (2020) · Blood · doi:10.1182/blood.2020007075 · Cited by 38
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 41
IDH1, lipid metabolism and cancer: Shedding new light on old ideas
Bogdanovic, E. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.04.014 · Cited by 39
Elevated citrate in pediatric astrocytomas with malignant progression
Blüml, S., Panigrahy, A., Laskov, M., Dhall, G., Krieger, M. D., Nelson, M., Finlay, J. L., & Gilles, F. H. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor087 · Cited by 38
Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
Ohba, S., & Hirose, Y. (2016) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2015-0322 · Cited by 38
Teng, Y. D., Abd‐El‐Barr, M. M., Wang, L., Hajiali, H., Wu, L., & ZAFONTE, R. D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.010 · Cited by 37
Zheng, S., & Tao, W. (2021) · Cancers · doi:10.3390/cancers13051013 · Cited by 38
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
Salati, M., Caputo, F., Baldessari, C., Galassi, B., Grossi, F., Dominici, M., & Ghidini, M. (2020) · Cancers · doi:10.3390/cancers12113310 · Cited by 42
Magnetic resonance spectroscopy for the study of cns malignancies
Ruiz‐Rodado, V., Brender, J., Cherukuri, M. K., Gilbert, M. R., & Larion, M. (2020) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2020.11.001 · Cited by 37
Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation
Fan, X., Fan, J., Yang, H., Zhao, C., Niu, W., Fang, Z., & Chen, X. (2021) · Oncogenesis · doi:10.1038/s41389-021-00361-8 · Cited by 38
Balañá, C., Castañer, S., Carrato, C., Morán, T., Lopez‐Paradís, A., Doménech, M., Hernández, A., & Puig, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.865171 · Cited by 39
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System
Nieto‐Sampedro, M., Valle‐Argos, B., Gómez‐Nicola, D., Fernández‐Mayoralas, A., & Nieto‐Díaz, M. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7685 · Cited by 39
The mechanisms of IDH mutations in tumorigenesis
Ye, D., Xiong, Y., & Guan, K. (2012) · Cell Research · doi:10.1038/cr.2012.51 · Cited by 38
Self-citationMolecular Imaging of Metabolic Reprograming in Mutant IDH Cells
Viswanath, P., Chaumeil, M. M., & Ronen, S. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00060 · Cited by 38
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Lv, S., Teugels, E., Sadones, J., Quartier, E., Huylebrouck, M., Four, S. D., Mercier, M. L., Witte, O. D., Salmon, I. J., Michotte, A., et al. (2011) · PubMed · Cited by 37
Li, M., Kales, S. C., Ma, K., Shoemaker, B. A., Crespo-Barreto, J., Cangelosi, A. L., Lipkowitz, S., & Panchenko, A. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3812 · Cited by 38
Ma, T., Peng, Y., Huang, W., Liu, Y., & Ding, J. (2017) · Scientific Reports · doi:10.1038/srep41882 · Cited by 37
Self-citationIdentification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
Trong, P. D., Roesch, S., Mairbäurl, H., Pusch, S., Unterberg, A. W., Herold‐Mende, C. C., & Warta, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102903 · Cited by 37
Oncogene addiction in gliomas: Implications for molecular targeted therapy
Yan, W., Zhang, W., & Jiang, T. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-58 · Cited by 37
Metadata
- Authors
- Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., Ding, J., Lei, Q., Guan, K.-L., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Molecular and Cell Biology Laboratory, Institute of Biomedical Sciences, Fudan University, 130 Dong-An Road, Shanghai 200032, China.
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Lin, Yan
- Xu, Wei
- Jiang, Wenqing
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Science
- Published
- 2009-04-10
- Volume
- 324
- Issue
- 5924
- Pages
- 261-265
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3251015
- OpenAlex
- W1964150693
- Cited by
- 1,119
- References
- 12
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 43 · 2023: 36 · 2022: 50 · 2021: 62 · 2020: 58 · 2019: 54 · 2018: 63 · 2017: 71 · 2016: 57 · 2015: 71 · 2014: 74 · 2013: 90 · 2012: 84
- FWCI
- 37.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA068377)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, isocitrate dehydrogenase, glioma, HIF-1α, alpha-ketoglutarate, heterodimer formation, tumor suppressor, hypoxia, carcinogenesis, brain tumors, enzyme activity
- MeSH terms
- Adolescent, Adult, Aged, Astrocytoma, Brain Neoplasms, Cell Line, Child, Female, Glioblastoma, Glioma, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Male, Middle Aged, Oligodendroglioma, Oxalates, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Mutant Proteins, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
